Cervical Cancer Market

Deepa Singh July 16, 2021

7 min read

Cervical Cancer occurs in the cells of the cervix and usually originates in the transformation zone of the cervix, and spreads to regional lymph nodes with parametrial invasion also common.

Most cases of cervical cancer are caused by infection with human papillomavirus (HPV). Apart from HPV, other factors that can also increase the risk include human immunodeficiency virus (HIV), chlamydia, smoking, obesity, family history of cervical cancer, a diet low in fruits and vegetables, taking birth control pills, and having three full-term pregnancies.

DelveInsight's "Cervical Cancer Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Cervical Cancer, historical and forecasted epidemiology as well as the Cervical Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some facts of the Cervical Cancer Market Report:

The incidence of cervical cancer in 7MM (US, UK, Germany, Italy, Spain, France & Japan) in 2020 is expected to be 43,712.In the 7MM, the USA is the major contributor to the cervical cancer market revenue in 2020, and the region is expected to hold its position in the upcoming years.Key companies propelling the market size include Regeneron, AstraZeneca, Lovance, Zeria Pharmaceutical, Seattle Genetics/Genmab, Agenus Bio, Roche, Akeso Biopharma and Vaccibody/Roche, among others.Launch of cervical cancer pipeline therapies, including Cemiplimab (Regeneron), Durvalumab (AstraZeneca), LN-145 (Iovance), Z-100 (Zeria Pharmaceutical), Tisotumab vedotin (Seattle Genetics/Genmab) in the next decade is expected to propel the market growth.

Request for Free Sample Report: https://www.delveinsight.com/sample-request/cervical-cancer-market

“As per WHO estimates, Cervical Cancer is the fourth most common cancer in women.”

Clinical presentation depends mainly on the location and extent of disease. Precancerous changes or very early stage disease are usually asymptomatic and are detected on a cervical smear. Symptoms usually appear when the tumour causes spontaneous or contact bleeding, or pain if lymph nodes are involved.

Typical cervical cancer symptoms are: unusual bleeding, such as in between periods, after sex, or after menopause, vaginal discharge that looks or smells different than usual, pain in the pelvis, needing to urinate more often, pain during urination etc.

All women are at risk for cervical cancer. It occurs most often in women over age 30. There’s more than one kind of cervical cancer.

Squamous cell carcinoma-This forms in the lining of cervix. It’s found in up to 90% of cases.Adenocarcinoma-This forms in the cells that produce mucus.Mixed carcinoma-This has features of the two other types.

DelveInsight estimated that cervical cancer is most often diagnosed in women between the ages of 35 and 44, with the average age at diagnosis being 50. The late diagnosis in women is a consequence of a lack of vaccination and screening in women in the early stages of their lives.

Request for Free Sample Report: https://www.delveinsight.com/sample-request/cervical-cancer-market

Some of the Cervical Cancer Companies are:

Regeneron PharmaceuticalsZeria PharmaceuticalAdvaxisAstraZenecaImmunitorAnd Many Others

Cervical cancer Drug Covered:

LibtayoZ-100ADXS11–001IMFINZV3-CervixAnd Many Others

Table of Contents:

1. Key Insights

2. Executive Summary of Cervical Cancer

3. Competitive Intelligence Analysis for Cervical Cancer

4. Cervical Cancer: Market Overview at a Glance

5. Cervical Cancer: Disease Background and Overview

6. Patient Journey